Background: Recent research demonstrated substantial heterogeneity in the Kidney Disease: Improving Global Outcomes (KDIGO) acute kidney injury (AKI) diagnosis and staging criteria implementations in clinical research. Here we report an additional issue in the implementation of the criteria: the incorrect description and application of a stage 3 serum creatinine (SCr) criterion. Instead of an increase in SCr to or beyond 4.0 mg/dL, studies apparently interpreted this criterion as an increase in SCr by 4.0 mg/dL.
Methods: Using a sample of 8124 consecutive intensive care unit (ICU) admissions, we illustrate the implications of such incorrect application. The AKI stage distributions associated with the correct and incorrect stage 3 SCr criterion implementations were compared, both with and without the stage 3 renal replacement therapy (RRT) criterion. In addition, we compared chronic kidney disease presence, ICU mortality rates and hospital mortality rates associated with each of the AKI stages and the misclassified cases.
Results: Where incorrect implementation of the SCr stage 3 criterion showed a stage 3 AKI rate of 29%, correct implementation revealed a rate of 34%, mainly due to shifts from stage 1 to stage 3. Without the stage 3 RRT criterion, the stage 3 AKI rates were 9% and 19% after incorrect and correct implementation, respectively. The ICU and hospital mortality rates in cases misclassified as stage 1 or 2 were similar to those in cases correctly classified as stage 1 instead of stage 3.
Conclusions: While incorrect implementation of the SCr stage 3 criterion has significant consequences for AKI severity epidemiology, consequences for clinical decision making may be less severe. We urge researchers and clinicians to verify their implementation of the AKI staging criteria.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050561 | PMC |
| http://dx.doi.org/10.1093/ckj/sfab256 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Deep learning-based design and experimental validation of a medicine-like human antibody library.
Brief Bioinform
November 2024
Biotherapeutics Molecule Discovery, Boehringer Ingelheim Pharmaceutical Inc., 900 Ridgebury Road, Ridgefield, CT 06877, United States.
Antibody generation requires the use of one or more time-consuming methods, namely animal immunization, and in vitro display technologies. However, the recent availability of large amounts of antibody sequence and structural data in the public domain along with the advent of generative deep learning algorithms raises the possibility of computationally generating novel antibody sequences with desirable developability attributes. Here, we describe a deep learning model for computationally generating libraries of highly human antibody variable regions whose intrinsic physicochemical properties resemble those of the variable regions of the marketed antibody-based biotherapeutics (medicine-likeness).
View Article and Find Full Text PDFDynamic Importance of Genomic and Clinical Risk for Coronary Artery Disease Over the Life Course.
Circ Genom Precis Med
January 2025
Division of Cardiology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston. (S.M.U., K.P., B.T., A.C.F., P.N.).
Background: Earlier identification of high coronary artery disease (CAD) risk individuals may enable more effective prevention strategies. However, existing 10-year risk frameworks are ineffective at earlier identification. We sought to understand how the variable importance of genomic and clinical factors across life stages may significantly improve lifelong CAD event prediction.
View Article and Find Full Text PDFSex-Specific Clinical and Genetic Factors Associated With Adverse Outcomes in Hypertrophic Cardiomyopathy.
Circ Genom Precis Med
January 2025
Garvan Institute of Medical Research, University of New South Wales, Sydney, Australia. (A.B., J.S., A.C., J.I.).
Background: Females with hypertrophic cardiomyopathy present at a more advanced stage of the disease and have a higher risk of heart failure and death. The factors behind these differences are unclear. We aimed to investigate sex-related differences in clinical and genetic factors affecting adverse outcomes in the Sarcomeric Human Cardiomyopathy Registry.
View Article and Find Full Text PDFPhase II Trial of Brain MRI Surveillance in Stage IV Breast Cancer.
Neuro Oncol
January 2025
Department of Breast Oncology, Moffitt Cancer Center.
Background: Screening of asymptomatic stage IV breast cancer with brain MRIs is currently not recommended by National Comprehensive Cancer Network (NCCN) Guidelines. The incidence of asymptomatic brain metastasis is not well documented.
Methods: The study is designed as a single arm, phase II trial, with the goal of investigating surveillance brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.
Alkaptonuria (AKU) is an extremely rare autosomal recessive metabolic disorder caused by deficiency of homogentisic acid oxidase and resulting in accumulation of homogentisic acid in collagenous structures. It is characterized by a triad of homogentisic aciduria, bluish-black discoloration of connective tissues (ochronosis) and arthropathy of large weight bearing joints. We report on a middle-aged female patient with bilateral severe ochronotic arthritis of both hips and shoulder joints requiring total joint replacements as staged procedures which were done without complications offering a complete pain relief and a satisfactory clinical and functional outcome.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!